NASDAQ:TERN Terns Pharmaceuticals (TERN) Stock Price, News & Analysis $7.77 +0.27 (+3.60%) Closing price 04:00 PM EasternExtended Trading$8.06 +0.29 (+3.67%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Terns Pharmaceuticals Stock (NASDAQ:TERN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Terns Pharmaceuticals alerts:Sign Up Key Stats Today's Range$7.12▼$7.8650-Day Range$6.30▼$8.6252-Week Range$1.87▼$9.03Volume1.84 million shsAverage Volume1.49 million shsMarket Capitalization$679.95 millionP/E RatioN/ADividend YieldN/APrice Target$13.92Consensus RatingModerate Buy Company Overview Terns Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies. The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation. These include inhibitors of key pathways implicated in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), as well as programs directed at hepatocellular carcinoma. Each candidate is being investigated for its ability to modulate disease drivers such as bile acid metabolism, immune cell activation and cell‐signaling cascades involved in fibrosis. Terns leverages state‐of‐the‐art medicinal chemistry and translational biology platforms to optimize both efficacy and safety profiles across its portfolio. Headquartered in San Diego, California, Terns Pharmaceuticals operates in a hub known for innovation in hepatology and liver disease research. The company’s management and scientific leadership bring extensive experience from established biotech and pharmaceutical organizations, with deep expertise in clinical development, regulatory strategy and commercialization planning. By combining this leadership team’s industry knowledge with strategic partnerships and academic collaborations, Terns is positioned to advance its therapeutic candidates toward regulatory milestones and, ultimately, broaden treatment options for patients suffering from severe liver diseases.AI Generated. May Contain Errors. Read More Terns Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreTERN MarketRank™: Terns Pharmaceuticals scored higher than 79% of companies evaluated by MarketBeat, and ranked 191st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingTerns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialTerns Pharmaceuticals has a consensus price target of $13.92, representing about 79.2% upside from its current price of $7.77.Amount of Analyst CoverageTerns Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Terns Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.19) to ($1.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Terns Pharmaceuticals is -7.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Terns Pharmaceuticals is -7.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTerns Pharmaceuticals has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Terns Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.83% of the float of Terns Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTerns Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Terns Pharmaceuticals has recently decreased by 0.96%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTerns Pharmaceuticals does not currently pay a dividend.Dividend GrowthTerns Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-0.95 Percentage of Shares Shorted11.83% of the float of Terns Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTerns Pharmaceuticals has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Terns Pharmaceuticals has recently decreased by 0.96%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News Sentiment-0.07 News SentimentTerns Pharmaceuticals has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Terns Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for TERN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Terns Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,410.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Terns Pharmaceuticals is held by insiders.Percentage Held by Institutions98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Terns Pharmaceuticals' insider trading history. Receive TERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TERN Stock News HeadlinesJMP Securities Maintains Terns Pharmaceuticals (TERN) Market Outperform RecommendationOctober 23 at 11:55 PM | msn.comJMP Securities Maintains Terns Pharmaceuticals (TERN) Market Outperform RecommendationOctober 23 at 11:55 PM | msn.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.October 24 at 2:00 AM | Porter & Company (Ad)Terns Pharmaceuticals price target lowered to $15 from $20 at Citizens JMPOctober 23 at 9:04 AM | msn.comAfter a failure in red-hot GLP-1 weight-loss space, Peninsula biotech shifts focus to cancerOctober 22 at 8:34 PM | bizjournals.comTerns Pharmaceuticals: GLP-1 Obesity Drug Cut Warrants Downgrade To 'Hold' RatingOctober 22 at 4:11 PM | seekingalpha.comTerns Pharmaceuticals price target lowered to $9 from $14 at MizuhoOctober 22 at 3:34 PM | msn.comTerns Pharmaceuticals price target lowered to $14 from $15 at BarclaysOctober 22 at 8:59 AM | msn.comSee More Headlines TERN Stock Analysis - Frequently Asked Questions How have TERN shares performed this year? Terns Pharmaceuticals' stock was trading at $5.54 at the beginning of 2025. Since then, TERN shares have increased by 40.3% and is now trading at $7.77. How were Terns Pharmaceuticals' earnings last quarter? Terns Pharmaceuticals, Inc. (NASDAQ:TERN) released its earnings results on Tuesday, August, 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. When did Terns Pharmaceuticals IPO? Terns Pharmaceuticals (TERN) raised $101 million in an initial public offering on Friday, February 5th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO. Who are Terns Pharmaceuticals' major shareholders? Terns Pharmaceuticals' top institutional investors include Exchange Traded Concepts LLC (0.14%) and Voya Investment Management LLC (0.02%). Insiders that own company stock include Orbimed Advisors Llc, Hongbo Lu, Biosciences Fund V LP Lav, Vivo Opportunity, Llc, Mark J Vignola, Emil Kuriakose, Amy L Burroughs, Andrew Gengos, Melita Sun Jung and Jill M Quigley. View institutional ownership trends. How do I buy shares of Terns Pharmaceuticals? Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Terns Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Terns Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX). Company Calendar Last Earnings8/05/2025Today10/24/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TERN CIK1831363 Webwww.ternspharma.com Phone650-525-5535FaxN/AEmployees40Year Founded2017Price Target and Rating Average Price Target for Terns Pharmaceuticals$13.92 High Price Target$20.00 Low Price Target$7.44 Potential Upside/Downside+84.4%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-27.35% Return on Assets-26.18% Debt Debt-to-Equity RatioN/A Current Ratio24.70 Quick Ratio24.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book1.86Miscellaneous Outstanding Shares87,510,000Free Float86,198,000Market Cap$660.70 million OptionableNot Optionable Beta-0.03 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TERN) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.